44 results about "Ischemic injury" patented technology

This invention relates to the field of ischemic injury model construction technology, and particularly to a method for constructing a mouse ischemic injury model for evaluating the protective effect of GDF-15. The method includes acquiring a dataset of mouse physiological parameters to determine physiological feature vectors, thereby determining an individual vulnerability index and performing similarity matching with the vulnerability index of a specific individual. Based on the matching results, a matching sample set is constructed, and then an ischemic injury model is constructed using a deep learning network model. The model is then dynamically simulated using the specific individual vulnerability index, specific intermediate monitoring data, and specific infarct area percentage data to output a simulated protective effect index to determine if the model is qualified. If unqualified, the similarity matching threshold is adjusted based on the degree of deviation, and the matching and model construction are repeated. This invention significantly improves the uniformity and construction success rate of the ischemic injury model through individualized matching and dynamic feedback optimization, providing a reliable model for evaluating the protective effect of GDF-15.

This invention relates to the field of medical and health device technology, and discloses a wearable AI-assisted pressure-controlled ischemia pretreatment training device, including a support base. A support plate is fixedly connected to the inner side of the support base, and a restraint strap is detachably connected to the inner side of the support plate. Two airbags are installed inside the restraint strap. Two fixed cylinders are fixedly connected to the outer side of the support base. A connecting tube 1 and a connecting tube 2 are sequentially connected to the outer side of each fixed cylinder. The end of the connecting tube 2 away from the fixed cylinder is connected to the interior of the airbags. A movable plate is slidably connected inside the fixed cylinders, and a movable rod is fixedly connected to the outer side of the movable plate. By setting up airbags 1 and 2 and combining them with an AI pretreatment training system, coordinated ischemia and reperfusion training of two target organs (finger and arm) can be achieved. This dual-site training stimulates a stronger anti-ischemic injury protection mechanism in the body, broadening the applicable population and training scenarios of the device.

The application relates to a dual-purpose maintenance system for taking out a heart and maintaining the heart extracorporeally, which comprises a perfusion pipeline assembly and an organ box. The design that the organ box is communicated with a blood storage container and is switched can support the no-stop-taking-out and transportation operation of the heart. In the conversion process, the pipeline does not need to be replaced, the heat ischemic injury and ischemia-reperfusion injury of the heart are reduced.

Compounds, compositions and methods for improving the viability and / or function of cells or for the in vitro, ex vivo or in vivo protection of cells, tissue, graft or organs from various damages are described. The reagents and composition are based on activation of the heat shock response activation and / or the antioxidant response and include for example. HSP90 co-factor inhibitor such as Celastrol or Celastrol analogs used alone or in combination with an adjunct agent (e.g., a NRF-2 activator, antioxidant, etc.). Therapeutic enhancement may also include increase in paracrine effector production and signaling. Methods for improving the resistance of cells, tissue, grafts or organs to damages or stress, such as hypoxic or oxidative stress-induced cell death, and / or for improving the viability and retention of transplanted or transfused cells are also described. Therapeutic treatment or prevention of ischemic injury (e.g. myocardial infarct, ischemia / reperfusion injury) and related stressors (hypoxia, oxidative stress, inflammation, sepsis / shock, etc) are also provided.

The application belongs to the technical field of biological medicine, and particularly relates to umbilical cord mesenchymal stem cells and a preparation method and application thereof. The preparation method takes umbilical cord Wharton's jelly as raw material, and obtains high-purity umbilical cord mesenchymal stem cells through cleaning treatment, tissue block preparation, serum-free culture and liquid change subculture. The culture conditions and operation parameters are strictly controlled in the preparation process, the MSC serum-free culture medium and trypsin substitutes are used, so that the cell activity and purity can be guaranteed. The umbilical cord mesenchymal stem cells have no obvious toxicity and tumorigenic risk under a safe dose, and have no damage to organs in long-term use. The umbilical cord mesenchymal stem cells can significantly improve the motor dysfunction after cerebral ischemia, reduce the volume of cerebral ischemic injury, protect the integrity of the blood-brain barrier, reduce the neuroinflammatory response, and play a multi-dimensional role in brain tissue protection and repair, thereby providing a new effective means for the treatment of ischemic stroke, and having important clinical transformation value and application prospect.

The invention discloses a screening method of anti-cerebral ischemic injury active components of a salvia miltiorrhiza-cortex moutan medicine, a targeted brain-entering composition and application thereof, and belongs to the technical field of traditional Chinese medicines. The pharmaceutical composition for resisting cerebral ischemic injury is prepared by compatibility of radix salviae miltiorrhizae and cortex moutan, blood-entering active components of the pharmaceutical composition comprise various components such as gallic acid, and paeoniflorin and the like are targeted brain-entering components. The invention also provides a method for screening the active ingredients of the composition in blood, which comprises the following steps: preparing a test sample and a mixed reference substance solution, and analyzing and determining the ingredients by high performance liquid chromatography and high resolution mass spectrometry. The composition can be used for preparing drugs for resisting cerebral ischemia injury, can improve the neurological function of rats and the like, and is suitable for treating acute and chronic cerebral ischemia and reperfusion injury. In addition, the active ingredients entering blood can be used for preparing drugs for promoting angiogenesis of cerebral vessels, and the BMECs related capacity of OGD / R damaged rats is improved. The invention provides a new direction and choice for treatment of cerebral ischemia injury.

The application relates to the technical field of biological medicine, and discloses medical uses of HSPD1 acetylation modification in prevention or treatment of myocardial infarction. The application first finds that the acetylation level of an HSPD1 protein K352 site is specifically up-regulated in the pathological process of myocardial infarction, and that the heart function after myocardial infarction can be significantly improved by up-regulating the acetylation level of the site, and myocardial fibrosis and myocardial cell hypertrophy can be inhibited; the acetylation level of the site is down-regulated, and myocardial ischemic injury is aggravated, and the heart function is deteriorated. The application confirms that the HSPD1 K352 site acetylation can be used as a new target point for prevention, treatment and auxiliary diagnosis of myocardial infarction, and provides a theoretical basis and experimental basis for research and development of myocardial infarction targeted drugs and gene therapy products.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The application discloses a myocardial ischemic injury marker CAPG and application thereof. The application finds that down-regulation of CAPG expression can improve myocardial cell apoptosis and heart function after myocardial infarction by injecting AAV9-shCAPG virus into the tail vein of a mouse model of myocardial infarction. The application first discloses a new use of macrophage capping protein (CAPG) as a therapeutic target and a diagnostic target of myocardial ischemic injury, provides a new drug action target for diagnosis and treatment of myocardial ischemic injury, and has very important clinical transformation value. As a diagnostic marker of myocardial ischemic injury, CAPG can be conveniently detected by using an existing enzyme-linked immunosorbent assay kit, has the advantage of rapid detection, and can be conveniently detected by only extracting a small amount of peripheral venous blood of a patient.

The present invention provides a pharmaceutical composition, which is an aqueous solution containing Compound (I) (also known as U0126) or a pharmaceutically acceptable salt thereof at a concentration of 50-200 μM, further comprising 0.2-1.0% (v / v) polyoxyethylene castor oil. The composition is particularly useful in treating ischemic injury (particularly subarachnoid hemorrhage) in human patients by direct injection into the brain. Uses of the composition, unit doses containing the composition, and methods of using the composition are also disclosed. [Formula 1] TIFF2026501344000012.tif40159

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The application discloses application of Angelica acutiloba Nakai lactone A in preparation of a product for resisting myocardial ischemic injury, and the myocardial ischemic injury is an increase in cell membrane permeability of myocardial cells or apoptosis, necrosis and fragmentation of the myocardial cells, and the product is a drug or a pharmaceutical preparation. In the application, the Angelica acutiloba Nakai lactone A has low toxicity to normal cells, is derived from traditional Chinese medicines of Angelica and Chuanxiong, is safe, has low preparation cost, and can be used as a promising drug for protecting myocardial cells from injury caused by ischemia.

The invention discloses a small molecule activator targeting nerve cell aromatase and application of the small molecule activator in cerebral ischemia injury, and belongs to the technical field of biological medicine. The activator can directly enhance the catalytic activity of aromatase without significantly affecting the gene transcription of aromatase, so that the local estrogen level in the brain is accurately improved, and the neuroprotection effect is achieved. The neuron aromatase is specifically activated, so that the side effect of systemic estrogen treatment is avoided. In-vivo and in-vitro experiments prove that the concentration of estrogen in a target region can be effectively improved through local intracerebral administration, and the survival rate of neurons in an oxygen-glucose deprivation / reoxygenation injury model is remarkably improved. The pharmaceutical composition provided by the invention is suitable for local administration or systemic administration of a central nervous system, can be combined with the existing therapy, and provides a brand new treatment strategy and drug candidate for cerebral ischemia injury.

Described herein are compositions and methods for treating ischemic injury in a subject comprising administering a therapeutically effective amount of an acellular amniotic fluid (acAF) to an ischemic injury situs within a therapeutic time window.

Provided are materials and methods for rejuvenating an ex vivo organ prior to transplantation of the organ into a subject in need thereof. The methods and materials can be used, for example, to treat, ameliorate, rejuvenate, and / or regenerate organs, e.g., kidneys and livers, that are of old age and / or characterized by organ damage due to an ischemic injury, a toxic injury, a perfusion injury, a hypertensive injury, an immune injury, a physical injury, steatosis, virus induced hepatitis, alcohol, or fibrosis not associated with any known cause. The materials and methods provided can increase the pool of available donor organs, e.g., kidneys and livers. Furthermore, the materials and methods provided can treat an organ that is then self-transplanted.

A fixation device for the treatment of diabetic peripheral neuropathy, belonging to the field of fixation technology, aims to address the problem that prolonged pressure on the same location during long-term treatment can easily lead to pressure marks, ischemic injuries, or even pressure sores. The invention includes a bed frame with two placement plates fixedly installed on one side. A lifting seat is fixedly installed on the surface of each placement plate. Three moving parts are evenly distributed below the lifting seats. A driving component is fixedly installed on one side of the lifting seats. Three adjusting seats are slidably connected to the surfaces of the three moving parts. A first rolling pressure plate is fixedly installed at one end of the adjusting seat in the middle position, and a second rolling pressure plate is rotatably connected to one end of the adjusting seats on either side. This invention allows for switching between different pressure points, avoiding prolonged pressure on the same location and preventing the risk of local tissue ischemia and necrosis. Furthermore, it maintains the fixation of the lower leg while switching between different pressure points, improving the stability of the lower leg during treatment.

The invention discloses a tension adjusting system and method of an incision retractor, and relates to the technical field of medical instruments, the tension adjusting system comprises a flexible channel, a built-in ring is arranged at the far end of the flexible channel, and a fixed base is arranged at the near end of the flexible channel; the central tension adjusting system comprises a plurality of first adjusting belts, the first adjusting belts are embedded in the wall of the flexible channel and evenly distributed in the circumferential direction of the flexible channel, and the far ends of the first adjusting belts are fixedly connected with the far-end built-in ring. According to the invention, through dual mechanisms of manual central adjustment and automatic cooperative adjustment and in combination with a unique non-equilibrium compensation mode, precise, stable and adaptive control of the retraction force of the surgical incision is realized, so that the uniformity and stability of exposure of the surgical field are remarkably improved; and tissue ischemia injury caused by overlarge local pressure can be effectively avoided, and meanwhile, the operation convenience of a doctor and the safety of an operation process are enhanced.

The invention belongs to the technical field of biology, and particularly relates to related tRF for detecting myocardial ischemia injury and a detection method and application thereof. The invention provides a marker for myocardial ischemic injury, the marker is CIAtRF, and the nucleotide sequence of the CIAtRF is as shown in SEQ ID NO: 1. The expression of CIAtRF is up-regulated during myocardial injury, and CIAtRF participates in regulation and control of myocardial ischemic injury. The CIAtRF antiagomir provided by the invention can be used as an active ingredient in a product for treating myocardial ischemia reperfusion injury. By using the CIAtRF antiagomir, the expression of CIAtRF in the heart can be inhibited, the myocardial infarction area can be obviously inhibited, the fibrosis area can be reduced, and the survival rate of myocardial cells can be increased, so that myocardial ischemic injury is relieved, and the effect of improving the cardiac function is realized.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

The application provides a Pediococcus pentosaceus strain NCU16V with thrombus prevention and cerebral ischemic injury prevention, a microbial inoculum containing the same and application, and relates to the technical field of microorganisms.The preservation number of the Pediococcus pentosaceus strain NCU16V is CGMCC No.35427.The Pediococcus pentosaceus strain NCU16V has good gastrointestinal digestion tolerance, and has a high survival rate after being digested in simulated artificial gastric juice and intestinal juice for 3 hours, as verified by the research of the application.Meanwhile, it is verified that the Pediococcus pentosaceus strain NCU16V and the microbial inoculum containing the same can be widely applied in drugs for preventing thrombosis, drugs for relieving brain tissue injury after cerebral ischemia and preparation of ginkgo fermented products with thrombosis prevention.

In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In certain embodiments, the methods involve administering human induced pluripotent glial enriched progenitor cells into the brain of the subject.

A maleate salt of the compound of Formula (I) is provided: Crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; inflammatory or fibrotic diseases, cancer, epilepsy, Parkinson's disease, and Lafora disease.

The invention discloses application of primaquine in preparation of a medicine for inhibiting ferroptosis of neurons, and belongs to the technical field of biological medicine. The invention provides an application of primaquine in preparation of a medicine for inhibiting ferroptosis. In addition, the invention further provides application of the primaquine in preparation of drugs for protecting neurons or drugs for treating glaucoma. In addition, the invention also provides application of the primaquine in preparation of medicines for treating and / or preventing ischemic injury eye diseases. The primaquine provided by the invention can effectively inhibit ferroptosis.

The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia / macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.

The present invention addresses the problem of providing a new ischemic disease treatment strategy targeting pericytes. As a solution, the present invention provides an inflammation suppressant or a tissue protective agent for ischemic injury, each including an inhibitor which blocks ATP-sensitive potassium (KATP) channels present in a pericyte. In particular, the KATP channel is composed of pore-forming KIR6.1 and regulatory SUR2 subunits, and it is preferable for the inhibitor to act on the KIR6.1. The inflammation suppressant or the tissue protective agent for ischemic injury is preferably used in the treatment of ischemic diseases such as cerebral infarction or ischemic cardiac disease.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a short peptide entrapped by lung-targeted liposome and used for blocking combination of PKM2-FOXO3A in preparation of a medicine for treating stroke-related lung injury, the amino acid sequence of the short peptide is shown as SEQ ID NO.1, the SEQ ID NO.1 RKGEDREGKR and Pe (at) P-Lipo can be used for remarkably relieving MCAO mouse lung tissue pathological injury, and can be used for preparing a medicine for treating stroke-related lung injury. According to the present invention, with the application of the cerebral ischemia injury in the lung, the total reactive oxygen species (ROS) level in the lung tissue and the mitochondrial ROS level, the reduction of the ATP content can be reversed, the level of the lung tissue inflammation-related protein can be reduced, and the enrichment of PKM2, FOXO3A and TXNIP in the mitochondria can be reduced so as to alleviate the lung tissue oxidative stress and the mitochondrial injury caused by the cerebral ischemia injury, and provide the lung protection effect;